Scarica l'app Stockscreener
13.69
0.80%
-0.11
Dopo l'orario di chiusura:
13.80
0.11
+0.80%
Precedente Chiudi:
$13.80
Aprire:
$13.93
Volume 24 ore:
1.26M
Relative Volume:
1.23
Capitalizzazione di mercato:
$1.76B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-6.3515
EPS:
-2.1554
Flusso di cassa netto:
-
1 W Prestazione:
-9.64%
1M Prestazione:
-15.91%
6M Prestazione:
-0.44%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$13.30
$14.30
Intervallo di 1 settimana:
$13.30
$15.61
Portata 52W:
$11.00
$22.67
Generate Biomedicines Inc Stock (GENB) Company Profile
Nome
Generate Biomedicines Inc
Settore
Industria
Telefono
888-469-0055
Indirizzo
101 SOUTH STREET, SUITE 900, SOMERVILLE
Compare GENB vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
13.69 | 1.94B | 0 | 0 | 0 | -2.1554 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Iniziato | H.C. Wainwright | Buy |
| 2026-03-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-03-24 | Iniziato | Goldman | Buy |
| 2026-03-24 | Iniziato | Guggenheim | Buy |
| 2026-03-24 | Iniziato | Morgan Stanley | Overweight |
| 2026-03-24 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Generate Biomedicines Inc Borsa (GENB) Ultime notizie
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer | Newswise - Newswise
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial Of ‘Armored’ Car T Therapy For Ovarian Cancer - TradingView
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer - Carroll County Mirror-Democrat
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
Generate Biomedicines at Bernstein healthcare forum: data, not models By Investing.com - Investing.com Canada
Generate Biomedicines (GENB) Institutional Ownership 2026 - MarketBeat
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to S&P Global BMI Index - marketscreener.com
Generate Biomedicines Q2 2026 Earnings: Narrower-Than-Feared Loss Fails to Mask EPS Miss as Stock Rallies 5.93%Product Revenue Analysis - careplusvn.com
Generate Biomedicines (GENB) Slips 3.15% as Shares Test Support Near $15Max Pain Level - dars.gov.et
Generate Biomedicines at H.C. Wainwright: platform bets take center stage By Investing.com - Investing.com Canada
Generate Biomedicines at H.C. Wainwright: platform bets take center stage - Investing.com
Generate Biomedicines at Morgan Stanley conference: AI pipeline grows By Investing.com - Investing.com UK
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Generate Biomedicines at Cantor healthcare conference: pipeline gains traction By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy on Generate Biomedicines stock By Investing.com - Investing.com Australia
Generate Biomedicines (GENB) Slips 3% as Shares Test Key Support at $15.11Imbalance Zone - dars.gov.et
Generate Biomedicines to Present at Upcoming Investor Conferences - Quiver Quantitative
Five September talks will stream online from Generate Biomedicines - Stock Titan
Generate Biomedicines (GENB) Stock Price, News & Analysis - MarketBeat
Layoff Tracker: TScan axes 75% of workforce, prioritizes solid tumor program - BioSpace
Director at Generate Biomedicines (GENB) sells 1,000 shares near $16 - Stock Titan
Frances Arnold plans 2026 stock sale in Generate Biomedicines (NASDAQ: GENB) - Stock Titan
Director at Generate Biomedicines (GENB) lines up a major stock sale - Stock Titan
Generate Biomedicines stock price target raised to $30 by H.C. Wainwright on asthma data - Investing.com UK
H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Generate Biomedicines Is Maintained at Buy by HC Wainwright & Co. - Moomoo
Generate Biomedicines discloses early respiratory drug data after congress poster leak - Endpoints News
Companies Like Generate Biomedicines (NASDAQ:GENB) Are In A Position To Invest In Growth - simplywall.st
Nvidia GPUs Are Table Stakes in AI Drug Discovery, Generate Biomedicines CTO Says - finance.biggo.com
Generate Biomedicines Reports Premature Release of GB-0895 Clinical Posters Ahead of ERS Congress 2026 - Kalkine Media
Generate Biomedicines Stock Slides 20% as 103 Million Shares Clear Lock-Up - ts2.tech
Certain Warrants of Generate Biomedicines, Inc. are subject to a Lock-Up Agreement Ending on 26-AUG-2026. - marketscreener.com
Generate Biomedicines shares jump 20% ahead of post-IPO lock-up expiry - Pluang
Nvidia backs Generate Biomedicines in AI drug discovery push - scanx.trade
Generate Biomedicines Inc (NASDAQ:GENB) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Generate Biomedicines Inc's (NASDAQ:GENB) Lock-Up Period To End on August 26th - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Shares Up 4.9%Still a Buy? - MarketBeat
8 Stocks Nvidia Has Invested In - U.S. News Money
Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Generate Biomedicines (GENB) Stock Trends and Sentiment 2026 - MarketBeat
Q3 EPS Estimate for Generate Biomedicines Lowered by Analyst - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Generate Biomedicines Shares Fall Following Q2 Financial Results - marketscreener.com
Earnings Flash (GENB) Generate Biomedicines Inc. Reports Q2 Revenue $6.3M - marketscreener.com
Generate Biomedicines Inc Azioni (GENB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):